A Phase 1 interventional study of Daprodustat (GSK1278863) in Anaemia, sponsored by GlaxoSmithKline. Completed at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-04.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing GSK1278863 in Anemia — 1 open to participants now, 1 under way, 1 of them phase 3. GSK1278863 · Anemia.
Among the 30 studies testing GSK1278863 in Anemia, this one is the 21st largest by enrollment, is one of 4 that started in 2017, is one of 10 in phase 1, and was the 21st registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →1 of the 30 studies testing GSK1278863 in Anemia is open now. Recruiting first, the newest first:
GSK1278863: first FDA approval 2023 (JESDUVROQ). What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is below the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 76 across the 30 interventional studies. Of the 29 that completed or were terminated, 23 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 30 have an industry lead sponsor. The 3 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
35 studies in Anemia by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 35 finished, 25 (71%) have results posted.
Among the 35 studies in Anemia by GlaxoSmithKline, this one is the 23rd largest by enrollment, is one of 4 that started in 2017, is one of 14 in phase 1, and was the 27th registered.
GlaxoSmithKline’s Anemia studies by the year they started, since 2006.
1 of the studies testing GSK1278863 in Anemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07300111Phase 3Qilu Pharmaceutical Co., Ltd.A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD) | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies testing GSK1278863 in Anemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 35 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Daprodustat (GSK1278863), is a small molecule currently in development for the treatment of anemia of chronic kidney disease (CKD). Results of the earlier studies shows that liver is involved in the clearance of Daprodustat and hence, hepatic impairment can affect Daprodustat levels in the body. This single dose study will assess the effect of liver impairment on the pharmacokinetics (PK) and pharmacodynamics (PD) of daprodustat. The study will be conducted in two parts, Part 1 will include subjects with moderate hepatic impairment and matched healthy control subjects whereas Part 2 will include subjects will either mild or severe hepatic impairment and matched healthy control subjects. Approximately 8 subjects will be included in each of the group and all subjects will receive 6 milligram (mg) of daprodustat as a single oral dose in the fasted state. Total duration of participation in the study for a subject will be up to 7 weeks.
Inclusion Criteria:
For all subjects:
Additional inclusion criteria for Hepatically-Impaired subjects:
Additional inclusion criteria for healthy control subjects:
Exclusion Criteria:
For all subjects:
Exclusion criteria for Hepatically-Impaired subjects:
Exclusion criteria for healthy control subjects:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Approximately 8 subjects with moderate hepatic impairment will receive 6 mg of daprodustat as a single oral dose in the fasted state. This group will include at least one subject with a Child-Pugh score of 7, one with a score of 8 and one with a score of 9. The group will also include at least one female and at least one male subject.
Drug: Daprodustat (GSK1278863)
Approximately 8 healthy controls, matched in gender, age and BMI to subjects with moderate hepatic impairment, will receive 6 mg of daprodustat as a single oral dose in the fasted state. The group will include at least one female and at least one male subject.
Drug: Daprodustat (GSK1278863)
Approximately 8 subjects with mild or severe hepatic impairment will receive 6 mg of daprodustat as a single oral dose in the fasted state. This group will include at least one subject with a Child-Pugh score of 5 and one with a score of 6 for mild hepatic impairment and at least one subject with a Child-Pugh score of 10 or 11 and one with a score of 12 or 13 for severe hepatic impairment. The group will also include at least one female and at least one male subject.
Drug: Daprodustat (GSK1278863)
Approximately 8 healthy controls, matched in gender, age and BMI to subjects with mild or severe hepatic impairment, will receive 6 mg of daprodustat as a single oral dose in the fasted state. The group will include at least one female and at least one male subject.
Drug: Daprodustat (GSK1278863)
Daprodustat (GSK1278863) 6 mg tablet will be given to all subjects as a single dose via oral route. Daprodustat (GSK1278863) is a 9.0 millimeter (mm) round, compound radius, white film coated tablet.
Part 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-infinity]) of GSK1278863 and Its Metabolites
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), and GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods. Pharmacokinetic Population comprised of all participants in the Safety Population for whom a pharmacokinetic sample was obtained and analyzed.
Time frame: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose
Part 2: AUC (0-infinity) of GSK1278863 and Its Metabolites
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2) , GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), and GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose
Part 1: Percentage of AUC (0-infinity) Obtained by Extrapolation (Percentage AUCex) of GSK1278863 and Its Metabolites
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), and GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose
Part 2: Percentage AUCex of GSK1278863 and Its Metabolites
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose
Part 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration (AUC [0-t]) of GSK1278863 and Its Metabolites
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose
Part 2: AUC (0-t) of GSK1278863 and Its Metabolites
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose
Part 1: Maximum Observed Concentration (Cmax) of GSK1278863 and Its Metabolites
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose
Part 2: Cmax of GSK1278863 and Its Metabolites.
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), and GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose
Part 1: Apparent Terminal Phase Half-life (t1/2) of GSK1278863 and Its Metabolites
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose
Part 2: T1/2 of GSK1278863 and Its Metabolites
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose
Part 1: Time of Occurrence of Cmax (Tmax) of GSK1278863 and Its Metabolites
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose
Part 2: Tmax of GSK1278863 and Its Metabolites
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose
Part 1: Unbound Concentration in Plasma of GSK1278863 and Its Metabolites
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: 3 hours, 12 hours and 24 hours post-dose
Part 2: Unbound Concentration in Plasma of GSK1278863 and Its Metabolites
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.
Time frame: 3 hours, 12 hours and 24 hours post-dose
Part 1: Unbound Fraction in Plasma of GSK1278863 and Its Metabolites
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818, GSK2506102, GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods. Unbound fraction is the percentage of unbound drug in plasma calculated as unbound concentration divided by total concentration.
Time frame: 3 hours, 12 hours and 24 hours post-dose
Part 2: Unbound Fraction in Plasma of GSK1278863 and Its Metabolites
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites (GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13)). Pharmacokinetic parameters were determined using standard non-compartmental methods. Unbound fraction is the percentage of unbound drug in plasma calculated as unbound concentration divided by total concentration.
Time frame: 3 hours, 12 hours and 24 hours post-dose
Part 1: Maximum Observed Erythropoietin Concentration (Cmax, EPO) Following Administration of GSK1278863
Venous blood samples were collected for measurement of plasma EPO at the indicated time points. Pharmacodynamic Population comprised of all participants in the Safety Population who had at least one pharmacodynamic assessment.
Time frame: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose
Part 2: Cmax, EPO Following Administration of GSK1278863
Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863.
Time frame: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose
Part 1: Time of the Maximum Observed Erythropoietin Concentration (Tmax, EPO) Following Administration of GSK1278863
Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863.
Time frame: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose
Part 2: Tmax, EPO Following Administration of GSK1278863
Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863.
Time frame: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose
Part 1: Erythropoietin Area Under the Concentration-time Curve From Time Zero (Pre-dose) to the Last Time of Quantifiable Concentration (AUC [0-t, EPO]) Following Administration of GSK1278863
Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863.
Time frame: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose
Part 2: AUC (0-t, EPO) Following Administration of GSK1278863
Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863.
Time frame: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose
Part 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation as per Medical or scientific judgment. Safety Population comprised of all participants who received at least one dose of study medication.
Time frame: Up to 16 days
Part 2: Number of Participants With AEs and SAEs
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation as per Medical or scientific judgment.
Time frame: Up to 16 days
Part 1: Number of Participants With Worst Case Hematology Results Relative to Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline
Blood samples were collected for analysis of hematocrit, hemoglobin, leukocytes, lymphocytes, neutrophils and platelets. PCI ranges were \<0.075 or \>0.54 proportion of red blood cells in blood for hematocrit, \<25 or \>180 grams per liter (g/L) for hemoglobin, \<3 or \>20 x10\^9 cells per liter (cells/L) for leukocytes, \<0.8 x10\^9 cells/L for lymphocytes, \<1.5 x10\^9 cells/L for neutrophils, and \<100 or \>550 x10\^9 cells/L for platelet. Participants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (example given \[e.g.\], High to High), or whose value became within range, were recorded in "To within Range or No Change" category. Participants were counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Baseline is defined as latest non-missing scheduled pre-dose assessment.
Time frame: Baseline (Screening) and up to Day 16
Part 2: Number of Participants With Worst Case Hematology Results Relative to PCI Criteria Post-Baseline Relative to Baseline
Blood samples were collected for analysis of hematocrit, hemoglobin, leukocytes, lymphocytes, neutrophils and platelets. PCI ranges were \<0.075 or \>0.54 proportion of red blood cells in blood for hematocrit, \<25 or \>180 g/L for hemoglobin, \<3 or \>20 x10\^9 cells/L for leukocytes, \<0.8 x10\^9 cells/L for lymphocytes, \<1.5 x10\^9 cells/L for neutrophils, and \<100 or \>550 x10\^9 cells/L for platelet. Participants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in "To within Range or No Change" category. Participants were counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Baseline is defined as latest non-missing scheduled pre-dose assessment.
Time frame: Baseline (Screening) and up to Day 16
Part 1: Number of Participants With Worst Case Chemistry Results Relative to PCI Criteria Post-Baseline Relative to Baseline
Blood samples were collected for analysis of following parameters. PCI ranges were \<30g/L (albumin), \<2 or \>2.75 millimoles/L(mmol/L) (calcium), \<3 or \>9mmol/L(glucose), \>=2 times Upper limit of Normal(ULN) units/L(U/L) (alanine aminotransferase \[ALT\]), \>=2 times ULN U/L (alkaline phosphatase), \>=2 times ULN U/L(aspartate aminotransferase \[AST\]), \>=1.5 times ULN micromoles/L (µmol/L)(bilirubin), \<3 or \>5.5mmol/L(potassium), and \<130 or \>150mmol/L(sodium). Participants were counted in worst case category that their value changes to (low,within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in To within Range or No Change category. Participants were counted twice if participant has values that changed To Low and To High, so the percentages may not add to 100%. Baseline is defined as latest non-missing scheduled pre-dose assessment.
Time frame: Baseline (Screening) and up to Day 16
Part 2: Number of Participants With Worst Case Chemistry Results Relative to PCI Criteria Post-Baseline Relative to Baseline
Blood samples were collected for analysis of following parameters. PCI ranges were \<30g/L (albumin), \<2 or \>2.75 mmol/L (calcium), \<3 or \>9mmol/L (glucose), \>=2 times ULN U/L (ALT), \>=2 times ULN U/L (alkaline phosphatase), \>=2 times ULN U/L (AST), \>=1.5 times ULN µmol/L (bilirubin), \<3 or \>5.5 mmol/L (potassium), and \<130 or \>150 mmol/L (sodium). Participants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in To within Range or No Change category. Participants were counted twice if the participant has values that changed To Low and To High, so the percentages may not add to 100%. Baseline is defined as latest non-missing scheduled pre-dose assessment.
Time frame: Baseline (Screening) and up to Day 16
Part 1: Number of Participants With Abnormal Urinalysis Findings
Urine samples were collected at indicated time points for the analysis of urine parameters including specific gravity and Potential of hydrogen (pH) of urine, presence of glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, and leukocyte esterase in urine.
Time frame: Up to Day 16
Part 2: Number of Participants With Abnormal Urinalysis Findings
Urine samples were collected at indicated time points for the analysis of urine parameters including specific gravity and Potential of hydrogen (pH) of urine, presence of glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, and leukocyte esterase in urine.
Time frame: Up to Day 16
This was a two part study in adults with moderate (Part 1) and potentially mild (Part 2) hepatic impairment and matched, healthy control participants with normal hepatic function. This study was conducted at two centers in the United States of America (USA).
| Milestone | Part 1: Moderate Hepatic Impairment Participants | Part 1: Healthy Participants | Part 2: Mild Hepatic Impairment Participants | Part 2: Healthy Participants |
|---|---|---|---|---|
| Started | 8 | 8 | 0 | 0 |
| Completed | 8 | 8 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Moderate Hepatic Impairment Participants | Part 1: Healthy Participants | Part 2: Mild Hepatic Impairment Participants | Part 2: Healthy Participants |
|---|---|---|---|---|
| Started | 0 | 0 | 12 | 9 |
| Completed | 0 | 0 | 12 | 9 |
| Not completed | 0 | 0 | 0 | 0 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), and GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods. Pharmacokinetic Population comprised of all participants in the Safety Population for whom a pharmacokinetic sample was obtained and analyzed.
| Hour*nanogram per milliliter | Part 1: Moderate Hepatic Impairment Participants | Part 1: Healthy Participants |
|---|---|---|
| GSK1278863 | 296.2407 ± 111.1 | 148.3225 ± 31.7 |
| GSK2391220 (M2) | 77.6352 ± 56.9 | 47.1340 ± 30.9 |
| GSK2487818 (M4) | 47.5557 ± 67.4 | 28.9896 ± 30.3 |
| GSK2506102 (M5) | 16.8212 ± 43.9 | 11.2658 ± 29.4 |
| GSK2506104 (M3) | NA ± NA | NA ± NA |
| GSK2531398 (M6) | 33.9398 ± 49.2 | 20.9224 ± 27.7 |
| GSK2531401 (M13) | 52.0606 ± 34.0 | 39.6044 ± 32.1 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2) , GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), and GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Hour*nanogram per milliliter | Part 2: Mild Hepatic Impairment Participants | Part 2: Healthy Participants |
|---|---|---|
| GSK1278863 | 299.8773 ± 39.9 | 205.7559 ± 37.2 |
| GSK2391220 (M2) | 91.3799 ± 44.7 | 47.1647 ± 26.9 |
| GSK2487818 (M4) | 63.6211 ± 40.1 | 31.7637 ± 28.4 |
| GSK2506102 (M5) | 19.4020 ± 36.6 | 11.3374 ± 26.7 |
| GSK2506104 (M3) | 91.7692 ± 41.0 | 50.1154 ± 28.3 |
| GSK2531398 (M6) | 41.4666 ± 31.2 | 21.0066 ± 23.5 |
| GSK2531401 (M13) | 46.7001 ± 66.5 | 31.9797 ± 40.9 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), and GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Percentage of AUCex | Part 1: Moderate Hepatic Impairment Participants | Part 1: Healthy Participants |
|---|---|---|
| GSK1278863 | 0.0463 ± 0.03971 | 0.0486 ± 0.03445 |
| GSK2391220 (M2) | 0.1919 ± 0.14164 | 0.4176 ± 0.38893 |
| GSK2487818 (M4) | 0.5756 ± 0.89564 | 0.6763 ± 0.61031 |
| GSK2506102 (M5) | 0.6147 ± 0.17403 | 2.1559 ± 2.01781 |
| GSK2506104 (M3) | NA ± NA | NA ± NA |
| GSK2531398 (M6) | 0.2598 ± 0.10004 | 0.3689 ± 0.26189 |
| GSK2531401 (M13) | 0.2983 ± 0.27141 | 0.2787 ± 0.15617 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Percentage of AUCex | Part 2: Mild Hepatic Impairment Participants | Part 2: Healthy Participants |
|---|---|---|
| GSK1278863 | 0.1148 ± 0.26035 | 0.0601 ± 0.06032 |
| GSK2391220 (M2) | 0.2943 ± 0.32698 | 0.8105 ± 1.60084 |
| GSK2487818 (M4) | 0.2584 ± 0.30727 | 0.9054 ± 0.89147 |
| GSK2506102 (M5) | 0.5138 ± 0.22859 | 1.5924 ± 1.69300 |
| GSK2506104 (M3) | 0.2565 ± 0.28382 | 0.6875 ± 1.33005 |
| GSK2531398 (M6) | 0.2915 ± 0.25350 | 0.9412 ± 0.94415 |
| GSK2531401 (M13) | 0.2327 ± 0.23338 | 0.5256 ± 0.46352 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Hour*nanogram per milliliter | Part 1: Moderate Hepatic Impairment Participants | Part 1: Healthy Participants |
|---|---|---|
| GSK1278863 | 296.1035 ± 111.2 | 148.2504 ± 31.8 |
| GSK2391220 (M2) | 77.4861 ± 57.0 | 46.9368 ± 31.0 |
| GSK2487818 (M4) | 47.2803 ± 67.7 | 28.7930 ± 30.6 |
| GSK2506102 (M5) | 16.7177 ± 43.9 | 11.0208 ± 30.9 |
| GSK2506104 (M3) | NA ± NA | NA ± NA |
| GSK2531398 (M6) | 33.8516 ± 49.3 | 20.8451 ± 27.8 |
| GSK2531401 (M13) | 51.9052 ± 34.1 | 39.4939 ± 32.3 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Hour*nanogram per milliliter | Part 2: Mild Hepatic Impairment Participants | Part 2: Healthy Participants |
|---|---|---|
| GSK1278863 | 299.5322 ± 39.9 | 205.6322 ± 37.2 |
| GSK2391220 (M2) | 91.1105 ± 44.9 | 46.7771 ± 27.9 |
| GSK2487818 (M4) | 63.4564 ± 40.3 | 31.4750 ± 29.0 |
| GSK2506102 (M5) | 19.3023 ± 36.8 | 11.1555 ± 27.1 |
| GSK2506104 (M3) | 91.5334 ± 41.2 | 49.7669 ± 29.2 |
| GSK2531398 (M6) | 41.3456 ± 31.4 | 20.8080 ± 24.0 |
| GSK2531401 (M13) | 46.5914 ± 66.8 | 31.8113 ± 41.3 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Nanogram per milliliter | Part 1: Moderate Hepatic Impairment Participants | Part 1: Healthy Participants |
|---|---|---|
| GSK1278863 | 139.705 ± 108.8 | 70.607 ± 51.7 |
| GSK2391220 (M2) | 13.046 ± 46.2 | 10.199 ± 28.7 |
| GSK2487818 (M4) | 10.022 ± 55.0 | 8.025 ± 28.5 |
| GSK2506102 (M5) | 2.650 ± 34.6 | 2.245 ± 23.0 |
| GSK2506104 (M3) | NA ± NA | NA ± NA |
| GSK2531398 (M6) | 5.946 ± 41.7 | 4.672 ± 24.1 |
| GSK2531401 (M13) | 7.411 ± 35.0 | 7.120 ± 28.0 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), and GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Nanogram per milliliter | Part 2: Mild Hepatic Impairment Participants | Part 2: Healthy Participants |
|---|---|---|
| GSK1278863 | 113.232 ± 42.6 | 112.142 ± 35.7 |
| GSK2391220 (M2) | 15.792 ± 40.8 | 8.846 ± 40.0 |
| GSK2487818 (M4) | 13.614 ± 34.7 | 7.723 ± 35.6 |
| GSK2506102 (M5) | 3.241 ± 35.7 | 1.975 ± 33.4 |
| GSK2506104 (M3) | 15.475 ± 38.8 | 8.926 ± 37.9 |
| GSK2531398 (M6) | 7.333 ± 28.2 | 4.010 ± 31.7 |
| GSK2531401 (M13) | 6.791 ± 65.5 | 5.081 ± 43.4 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Hours | Part 1: Moderate Hepatic Impairment Participants | Part 1: Healthy Participants |
|---|---|---|
| GSK1278863 | 3.9867 ± 33.2 | 4.4054 ± 29.8 |
| GSK2391220 (M2) | 4.1830 ± 26.9 | 5.6415 ± 37.1 |
| GSK2487818 (M4) | 2.6559 ± 38.3 | 3.6385 ± 83.8 |
| GSK2506102 (M5) | 3.1966 ± 23.4 | 2.7314 ± 36.4 |
| GSK2506104 (M3) | NA ± NA | NA ± NA |
| GSK2531398 (M6) | 3.1287 ± 26.0 | 3.2641 ± 56.3 |
| GSK2531401 (M13) | 3.9432 ± 22.8 | 3.9414 ± 33.1 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Hours | Part 2: Mild Hepatic Impairment Participants | Part 2: Healthy Participants |
|---|---|---|
| GSK1278863 | 4.5251 ± 27.4 | 4.2792 ± 38.7 |
| GSK2391220 (M2) | 4.8118 ± 21.2 | 4.7439 ± 49.6 |
| GSK2487818 (M4) | 4.1059 ± 47.8 | 3.0578 ± 88.9 |
| GSK2506102 (M5) | 3.4087 ± 30.8 | 3.3108 ± 56.7 |
| GSK2506104 (M3) | 4.6675 ± 20.2 | 4.4967 ± 45.0 |
| GSK2531398 (M6) | 3.8096 ± 38.4 | 2.9947 ± 57.1 |
| GSK2531401 (M13) | 4.2869 ± 21.2 | 3.5510 ± 34.2 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Hours | Part 1: Moderate Hepatic Impairment Participants | Part 1: Healthy Participants |
|---|---|---|
| GSK1278863 | 1.50 (1.0 to 3.0) | 2.00 (1.0 to 3.0) |
| GSK2391220 (M2) | 3.00 (3.0 to 6.0) | 3.50 (2.0 to 4.0) |
| GSK2487818 (M4) | 3.00 (2.0 to 6.0) | 3.00 (1.5 to 4.0) |
| GSK2506102 (M5) | 3.50 (3.0 to 6.0) | 4.00 (2.0 to 4.0) |
| GSK2506104 (M3) | NA (NA to NA) | NA (NA to NA) |
| GSK2531398 (M6) | 3.50 (3.0 to 6.0) | 3.50 (2.0 to 4.0) |
| GSK2531401 (M13) | 4.00 (3.0 to 6.0) | 4.00 (3.0 to 6.0) |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Hours | Part 2: Mild Hepatic Impairment Participants | Part 2: Healthy Participants |
|---|---|---|
| GSK1278863 | 1.50 (1.0 to 3.0) | 1.50 (1.0 to 4.0) |
| GSK2391220 (M2) | 3.00 (3.0 to 4.0) | 3.00 (2.0 to 4.0) |
| GSK2487818 (M4) | 3.00 (2.0 to 4.0) | 3.00 (2.0 to 4.0) |
| GSK2506102 (M5) | 3.50 (3.0 to 4.0) | 3.00 (2.0 to 6.0) |
| GSK2506104 (M3) | 3.50 (3.0 to 4.0) | 3.00 (2.0 to 6.0) |
| GSK2531398 (M6) | 3.00 (3.0 to 4.0) | 3.00 (2.0 to 6.0) |
| GSK2531401 (M13) | 4.00 (3.0 to 4.0) | 4.00 (3.0 to 6.0) |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Nanograms per milliliter | Part 1: Moderate Hepatic Impairment Participants | Part 1: Healthy Participants |
|---|---|---|
| GSK1278863; 3 hours | 0.27989 ± 0.261668 | 0.11076 ± 0.070114 |
| GSK1278863; 12 hours | NA ± NA | NA ± NA |
| GSK1278863; 24 hours | NA ± NA | NA ± NA |
| GSK2391220 (M2); 3 hours | 4.47750 ± 1.779468 | 2.85875 ± 1.129961 |
| GSK2391220 (M2); 12 hours | 0.76525 ± 0.656087 | 0.22463 ± 0.119826 |
| GSK2391220 (M2); 24 hours | 0.06460 ± 0.089209 | 0.00963 ± 0.017963 |
| GSK2487818 (M4); 3 hours | 3.24463 ± 1.506964 | 1.86813 ± 0.760479 |
| GSK2487818 (M4); 12 hours | 0.29301 ± 0.338773 | 0.04769 ± 0.031411 |
| GSK2487818 (M4); 24 hours | 0.01201 ± 0.023617 | NA ± NA |
| GSK2506102 (M5); 3 hours | 0.64588 ± 0.242321 | 0.43175 ± 0.165059 |
| GSK2506102 (M5); 12 hours | 0.13024 ± 0.109089 | 0.04143 ± 0.031140 |
| GSK2506102 (M5); 24 hours | 0.00923 ± 0.026092 | NA ± NA |
| GSK2506104 (M3); 3 hours | 3.86250 ± 1.402241 | 2.57000 ± 1.010262 |
| GSK2506104 (M3); 12 hours | 0.71075 ± 0.601452 | 0.23938 ± 0.121781 |
| GSK2506104 (M3); 24 hours | 0.06315 ± 0.104994 | 0.00829 ± 0.015374 |
| GSK2531398 (M6); 3 hours | 1.42725 ± 0.552287 | 0.89338 ± 0.334179 |
| GSK2531398 (M6); 12 hours | 0.22973 ± 0.199514 | 0.06548 ± 0.035504 |
| GSK2531398 (M6); 24 hours | 0.01470 ± 0.028580 | NA ± NA |
| GSK2531401 (M13); 3 hours | 2.25375 ± 0.646771 | 2.03738 ± 0.807331 |
| GSK2531401 (M13); 12 hours | 0.63125 ± 0.379804 | 0.32075 ± 0.163981 |
| GSK2531401 (M13); 24 hours | 0.07580 ± 0.110738 | 0.01053 ± 0.020023 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods.
| Nanograms per milliliter | Part 2: Mild Hepatic Impairment Participants | Part 2: Healthy Participants |
|---|---|---|
| GSK1278863; 3 hours; n=6, 6 | 1.24213 ± 2.475347 | 0.15692 ± 0.138726 |
| GSK1278863; 12 hours; n=7, 6 | 0.04343 ± 0.114901 | 0.01527 ± 0.037396 |
| GSK1278863; 24 hours; n=7, 6 | NA ± NA | NA ± NA |
| GSK2391220 (M2); 3 hours; n=8, 7 | 5.32625 ± 2.139472 | 2.13700 ± 1.276959 |
| GSK2391220 (M2); 12 hours; n=8, 7 | 0.81263 ± 0.600031 | 0.24371 ± 0.079803 |
| GSK2391220 (M2); 24 hours; n=8, 7 | 0.30654 ± 0.729605 | NA ± NA |
| GSK2487818 (M4); 3 hours; n=8,7 | 3.91375 ± 1.441219 | 1.57633 ± 0.937244 |
| GSK2487818 (M4); 12 hours; n=8,7 | 0.40141 ± 0.560638 | 0.07793 ± 0.033300 |
| GSK2487818 (M4); 24 hours; n=8,7 | 0.00839 ± 0.015586 | 0.00454 ± 0.012019 |
| GSK2506102 (M5); 3 hours; n=8,7 | 0.78213 ± 0.314177 | 0.31091 ± 0.213793 |
| GSK2506102 (M5); 12 hours; n=8,7 | 0.25856 ± 0.425759 | 0.04796 ± 0.035510 |
| GSK2506102 (M5); 24 hours; n=8,7 | NA ± NA | NA ± NA |
| GSK2506104 (M3); 3 hours; n=8,7 | 4.68625 ± 1.839883 | 1.94271 ± 1.262970 |
| GSK2506104 (M3); 12 hours; n=8,7 | 0.75350 ± 0.496638 | 0.27014 ± 0.122830 |
| GSK2506104 (M3); 24 hours; n=8,7 | 0.04093 ± 0.029445 | 0.00819 ± 0.021657 |
| GSK2531398 (M6); 3 hours; n=8,7 | 1.86763 ± 0.713958 | 0.73530 ± 0.451869 |
| GSK2531398 (M6); 12 hours; n=8,7 | 0.34200 ± 0.412505 | 0.07879 ± 0.023474 |
| GSK2531398 (M6); 24 hours; n=8,7 | NA ± NA | NA ± NA |
| GSK2531401 (M13); 3 hours; n=8,7 | 2.47825 ± 0.965944 | 1.26771 ± 0.871839 |
| GSK2531401 (M13); 12 hours; n=8,7 | 0.75363 ± 0.597207 | 0.29429 ± 0.153615 |
| GSK2531401 (M13); 24 hours; n=8,7 | 0.29830 ± 0.720919 | 0.00454 ± 0.012019 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818, GSK2506102, GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods. Unbound fraction is the percentage of unbound drug in plasma calculated as unbound concentration divided by total concentration.
| Percentage of unbound drug in plasma | Part 1: Moderate Hepatic Impairment Participants | Part 1: Healthy Participants |
|---|---|---|
| GSK1278863; 3 hours; n=8, 8 | 0.0034 ± 0.00109 | 0.0028 ± 0.00019 |
| GSK1278863; 12 hours; n=8, 8 | NA ± NA | NA ± NA |
| GSK1278863; 24 hours; n=8,8 | NA ± NA | NA ± NA |
| GSK2391220 (M2); 3 hours; n=8,8 | 0.3379 ± 0.03573 | 0.3495 ± 0.05135 |
| GSK2391220 (M2); 12 hours; n=8,8 | 0.3540 ± 0.02186 | 0.3355 ± 0.02172 |
| GSK2391220 (M2); 24 hours; n=4,2 | 0.3861 ± 0.02827 | 0.3902 ± 0.07149 |
| GSK2487818 (M4); 3 hours; n=8,8 | 0.3080 ± 0.03085 | 0.2925 ± 0.01981 |
| GSK2487818 (M4); 12 hours; n=8,7 | 0.3071 ± 0.03419 | 0.2402 ± 0.02431 |
| GSK2487818 (M4); 24 hours; n=2,8 | 0.3508 ± 0.00191 | NA ± NA |
| GSK2506102 (M5); 3 hours; n=8, 8 | 0.2565 ± 0.04573 | 0.2441 ± 0.03397 |
| GSK2506102 (M5); 12 hours; n=8, 6 | 0.2517 ± 0.04022 | 0.2335 ± 0.02679 |
| GSK2506102 (M5); 24 hours; n=1, 8 | 0.2723 ± NA | NA ± NA |
| GSK2506104 (M3); 3 hours; n=8, 8 | NA ± NA | NA ± NA |
| GSK2506104 (M3); 12 hours; n=8, 8 | NA ± NA | NA ± NA |
| GSK2506104 (M3); 24 hours; n=8, 8 | NA ± NA | NA ± NA |
| GSK2531398 (M6); 3 hours; n=8, 8 | 0.2469 ± 0.04315 | 0.2461 ± 0.03264 |
| GSK2531398 (M6); 12 hours; n=8, 8 | 0.2550 ± 0.03166 | 0.2295 ± 0.01509 |
| GSK2531398 (M6); 24 hours; n=2, 8 | 0.3005 ± 0.03734 | NA ± NA |
| GSK2531401 (M13); 3 hours; n=8, 8 | 0.3519 ± 0.04431 | 0.3844 ± 0.06838 |
| GSK2531401 (M13); 12 hours; n=8, 8 | 0.3771 ± 0.02114 | 0.3565 ± 0.02558 |
| GSK2531401 (M13); 24 hours; n=6, 2 | 0.3817 ± 0.04449 | 0.3716 ± 0.02411 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites (GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13)). Pharmacokinetic parameters were determined using standard non-compartmental methods. Unbound fraction is the percentage of unbound drug in plasma calculated as unbound concentration divided by total concentration.
| Percentage of unbound drug in plasma | Part 2: Mild Hepatic Impairment Participants | Part 2: Healthy Participants |
|---|---|---|
| GSK1278863; 3 hours; n=6, 6 | 0.0134 ± 0.02369 | 0.0032 ± 0.00090 |
| GSK1278863; 12 hours; n=1, 1 | 0.1231 ± NA | 0.1246 ± NA |
| GSK1278863; 24 hours; n=8,7 | NA ± NA | NA ± NA |
| GSK2391220 (M2); 3 hours; n=8, 7 | 0.3191 ± 0.02263 | 0.3343 ± 0.06101 |
| GSK2391220 (M2); 12 hours; n=7, 7 | 0.3305 ± 0.03497 | 0.3174 ± 0.02174 |
| GSK2391220 (M2); 24 hours; n=5, 7 | 0.4099 ± 0.04797 | NA ± NA |
| GSK2487818 (M4); 3 hours; n=8, 7 | 0.2762 ± 0.02792 | 0.2857 ± 0.03897 |
| GSK2487818 (M4); 12 hours; n=7, 7 | 0.2850 ± 0.03110 | 0.2766 ± 0.03608 |
| GSK2487818 (M4); 24 hours; n=2, 1 | 0.3116 ± 0.07106 | 0.3387 ± NA |
| GSK2506102 (M5); 3 hours; n=8, 6 | 0.2339 ± 0.02704 | 0.2171 ± 0.06728 |
| GSK2506102 (M5); 12 hours; n=7, 6 | 0.2483 ± 0.03166 | 0.2191 ± 0.02903 |
| GSK2506102 (M5); 24 hours; n=8, 7 | NA ± NA | NA ± NA |
| GSK2506104 (M3); 3 hours; n=8, 7 | 0.2904 ± 0.02480 | 0.2938 ± 0.02618 |
| GSK2506104 (M3); 12 hours; n=7, 7 | 0.2970 ± 0.02959 | 0.2845 ± 0.02193 |
| GSK2506104 (M3); 24 hours; n=6, 1 | 0.3267 ± 0.03171 | 0.3016 ± NA |
| GSK2531398 (M6); 3 hours; n=8, 7 | 0.2491 ± 0.02989 | 0.2444 ± 0.04833 |
| GSK2531398 (M6); 12 hours; n=7, 7 | 0.2500 ± 0.03259 | 0.2346 ± 0.02031 |
| GSK2531398 (M6); 24 hours; n=8, 7 | NA ± NA | NA ± NA |
| GSK2531401 (M13); 3 hours; n=8, 7 | 0.3595 ± 0.02324 | 0.3569 ± 0.03504 |
| GSK2531401 (M13); 12 hours; n=7, 7 | 0.3527 ± 0.03957 | 0.3386 ± 0.01580 |
| GSK2531401 (M13); 24 hours; n=5, 1 | 0.4154 ± 0.03151 | 0.3845 ± NA |
Venous blood samples were collected for measurement of plasma EPO at the indicated time points. Pharmacodynamic Population comprised of all participants in the Safety Population who had at least one pharmacodynamic assessment.
| International units per liter | Part 1: Moderate Hepatic Impairment Participants | Part 1: Healthy Participants |
|---|---|---|
| Part 1: Maximum Observed Erythropoietin Concentration (Cmax, EPO) Following Administration of GSK1278863 | 48.898 ± 36.8476 | 28.391 ± 13.1904 |
Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863.
| International units per liter | Part 2: Mild Hepatic Impairment Participants | Part 2: Healthy Participants |
|---|---|---|
| Part 2: Cmax, EPO Following Administration of GSK1278863 | 43.933 ± 20.2602 | 45.871 ± 35.1537 |
Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863.
| Hours | Part 1: Moderate Hepatic Impairment Participants | Part 1: Healthy Participants |
|---|---|---|
| Part 1: Time of the Maximum Observed Erythropoietin Concentration (Tmax, EPO) Following Administration of GSK1278863 | 10.0 (8 to 12) | 10.0 (8 to 10) |
Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863.
| Hours | Part 2: Mild Hepatic Impairment Participants | Part 2: Healthy Participants |
|---|---|---|
| Part 2: Tmax, EPO Following Administration of GSK1278863 | 10.0 (0 to 48) | 10.0 (6 to 12) |
Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863.
| Hours* International units per liter | Part 1: Moderate Hepatic Impairment Participants | Part 1: Healthy Participants |
|---|---|---|
| Part 1: Erythropoietin Area Under the Concentration-time Curve From Time Zero (Pre-dose) to the Last Time of Quantifiable Concentration (AUC [0-t, EPO]) Following Administration of GSK1278863 | 1262.3724 ± 1148.34702 | 697.7140 ± 393.05978 |
Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863.
| Hours* International units per liter | Part 2: Mild Hepatic Impairment Participants | Part 2: Healthy Participants |
|---|---|---|
| Part 2: AUC (0-t, EPO) Following Administration of GSK1278863 | 1258.6211 ± 683.32848 | 1061.7549 ± 647.67154 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation as per Medical or scientific judgment. Safety Population comprised of all participants who received at least one dose of study medication.
| Participants | Part 1: Moderate Hepatic Impairment Participants | Part 1: Healthy Participants |
|---|---|---|
| Any SAE | 0 | 0 |
| Any AE | 1 | 2 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation as per Medical or scientific judgment.
| Participants | Part 2: Mild Hepatic Impairment Participants | Part 2: Healthy Participants |
|---|---|---|
| Any SAE | 0 | 0 |
| Any AE | 0 | 0 |
Blood samples were collected for analysis of hematocrit, hemoglobin, leukocytes, lymphocytes, neutrophils and platelets. PCI ranges were \<0.075 or \>0.54 proportion of red blood cells in blood for hematocrit, \<25 or \>180 grams per liter (g/L) for hemoglobin, \<3 or \>20 x10\^9 cells per liter (cells/L) for leukocytes, \<0.8 x10\^9 cells/L for lymphocytes, \<1.5 x10\^9 cells/L for neutrophils, and \<100 or \>550 x10\^9 cells/L for platelet. Participants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (example given \[e.g.\], High to High), or whose value became within range, were recorded in "To within Range or No Change" category. Participants were counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Baseline is defined as latest non-missing scheduled pre-dose assessment.
| Participants | Part 1: Moderate Hepatic Impairment Participants | Part 1: Healthy Participants |
|---|---|---|
| Hematocrit; To Low | 0 | 0 |
| Hematocrit; To within Range or No Change | 8 | 8 |
| Hematocrit; To High | 0 | 0 |
| Hemoglobin; To Low | 0 | 0 |
| Hemoglobin; To within Range or No Change | 8 | 8 |
| Hemoglobin; To High | 0 | 0 |
| Leukocytes; To Low | 1 | 0 |
| Leukocytes; To within Range or No Change | 7 | 8 |
| Leukocytes; To High | 0 | 0 |
| Lymphocytes; To Low | 0 | 0 |
| Lymphocytes; To within Range or No Change | 8 | 8 |
| Lymphocytes; To High | 0 | 0 |
| Neutrophils; To Low | 0 | 0 |
| Neutrophils; To within Range or No Change | 8 | 8 |
| Neutrophils; To High | 0 | 0 |
| Platelets; To Low | 0 | 0 |
| Platelets; To within Range or No Change | 8 | 8 |
| Platelets; To High | 0 | 0 |
Blood samples were collected for analysis of hematocrit, hemoglobin, leukocytes, lymphocytes, neutrophils and platelets. PCI ranges were \<0.075 or \>0.54 proportion of red blood cells in blood for hematocrit, \<25 or \>180 g/L for hemoglobin, \<3 or \>20 x10\^9 cells/L for leukocytes, \<0.8 x10\^9 cells/L for lymphocytes, \<1.5 x10\^9 cells/L for neutrophils, and \<100 or \>550 x10\^9 cells/L for platelet. Participants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in "To within Range or No Change" category. Participants were counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Baseline is defined as latest non-missing scheduled pre-dose assessment.
| Participants | Part 2: Mild Hepatic Impairment Participants | Part 2: Healthy Participants |
|---|---|---|
| Hematocrit; To Low | 0 | 0 |
| Hematocrit; To within Range or No Change | 12 | 9 |
| Hematocrit; To High | 0 | 0 |
| Hemoglobin; To Low | 0 | 0 |
| Hemoglobin; To within Range or No Change | 12 | 9 |
| Hemoglobin; To High | 0 | 0 |
| Leukocytes; To Low | 0 | 0 |
| Leukocytes; To within Range or No Change | 12 | 9 |
| Leukocytes; To High | 0 | 0 |
| Lymphocytes; To Low | 1 | 0 |
| Lymphocytes; To within Range or No Change | 11 | 9 |
| Lymphocytes; To High | 0 | 0 |
| Neutrophils; To Low | 0 | 0 |
| Neutrophils; To within Range or No Change | 12 | 9 |
| Neutrophils; To High | 0 | 0 |
| Platelets; To Low | 0 | 0 |
| Platelets; To within Range or No Change | 12 | 9 |
| Platelets; To High | 0 | 0 |
Blood samples were collected for analysis of following parameters. PCI ranges were \<30g/L (albumin), \<2 or \>2.75 millimoles/L(mmol/L) (calcium), \<3 or \>9mmol/L(glucose), \>=2 times Upper limit of Normal(ULN) units/L(U/L) (alanine aminotransferase \[ALT\]), \>=2 times ULN U/L (alkaline phosphatase), \>=2 times ULN U/L(aspartate aminotransferase \[AST\]), \>=1.5 times ULN micromoles/L (µmol/L)(bilirubin), \<3 or \>5.5mmol/L(potassium), and \<130 or \>150mmol/L(sodium). Participants were counted in worst case category that their value changes to (low,within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in To within Range or No Change category. Participants were counted twice if participant has values that changed To Low and To High, so the percentages may not add to 100%. Baseline is defined as latest non-missing scheduled pre-dose assessment.
| Participants | Part 1: Moderate Hepatic Impairment Participants | Part 1: Healthy Participants |
|---|---|---|
| ALT ; To Low | 0 | 0 |
| ALT;To within Range or No Change | 8 | 8 |
| ALT; To High | 0 | 0 |
| Albumin; To Low | 0 | 0 |
| Albumin; To within Range or No Change | 8 | 8 |
| Albumin; To High | 0 | 0 |
| Alkaline Phosphatase; To Low | 0 | 0 |
| Alkaline Phosphatase; To within Range or No Change | 8 | 8 |
| Alkaline Phosphatase; To High | 0 | 0 |
| AST; To Low | 0 | 0 |
| AST;To within Range or No Change | 8 | 8 |
| AST; To High | 0 | 0 |
| Bilirubin; To Low | 0 | 0 |
| Bilirubin; To within Range or No Change | 8 | 8 |
| Bilirubin; To High | 0 | 0 |
| Calcium; To Low | 0 | 0 |
| Calcium; To within Range or No Change | 8 | 8 |
| Calcium; To High | 0 | 0 |
| Glucose; To Low | 0 | 0 |
| Glucose; To within Range or No Change | 6 | 8 |
| Glucose; To High | 2 | 0 |
| Potassium; To Low | 0 | 0 |
| Potassium; To within Range or No Change | 8 | 8 |
| Potassium; To High | 0 | 0 |
| Sodium; To Low | 1 | 0 |
| Sodium; To within Range or No Change | 7 | 8 |
| Sodium; To High | 0 | 0 |
Blood samples were collected for analysis of following parameters. PCI ranges were \<30g/L (albumin), \<2 or \>2.75 mmol/L (calcium), \<3 or \>9mmol/L (glucose), \>=2 times ULN U/L (ALT), \>=2 times ULN U/L (alkaline phosphatase), \>=2 times ULN U/L (AST), \>=1.5 times ULN µmol/L (bilirubin), \<3 or \>5.5 mmol/L (potassium), and \<130 or \>150 mmol/L (sodium). Participants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in To within Range or No Change category. Participants were counted twice if the participant has values that changed To Low and To High, so the percentages may not add to 100%. Baseline is defined as latest non-missing scheduled pre-dose assessment.
| Participants | Part 2: Mild Hepatic Impairment Participants | Part 2: Healthy Participants |
|---|---|---|
| ALT ; To Low | 0 | 0 |
| ALT;To within Range or No Change | 12 | 9 |
| ALT ; To High | 0 | 0 |
| Albumin; To Low | 0 | 0 |
| Albumin; To within Range or No Change | 12 | 9 |
| Albumin; To High | 0 | 0 |
| Alkaline Phosphatase; To Low | 0 | 0 |
| Alkaline Phosphatase; To within Range or No Change | 12 | 9 |
| Alkaline Phosphatase; To High | 0 | 0 |
| AST; To Low | 0 | 0 |
| AST;To within Range or No Change | 12 | 9 |
| AST; To High | 0 | 0 |
| Bilirubin; To Low | 0 | 0 |
| Bilirubin; To within Range or No Change | 12 | 9 |
| Bilirubin; To High | 0 | 0 |
| Calcium; To Low | 0 | 0 |
| Calcium; To within Range or No Change | 12 | 9 |
| Calcium; To High | 0 | 0 |
| Glucose; To Low | 0 | 0 |
| Glucose; To within Range or No Change | 10 | 9 |
| Glucose; To High | 2 | 0 |
| Potassium; To Low | 0 | 0 |
| Potassium; To within Range or No Change | 12 | 9 |
| Potassium; To High | 0 | 0 |
| Sodium; To Low | 0 | 0 |
| Sodium; To within Range or No Change | 12 | 9 |
| Sodium; To High | 0 | 0 |
Urine samples were collected at indicated time points for the analysis of urine parameters including specific gravity and Potential of hydrogen (pH) of urine, presence of glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, and leukocyte esterase in urine.
| Participants | Part 1: Moderate Hepatic Impairment Participants | Part 1: Healthy Participants |
|---|---|---|
| Part 1: Number of Participants With Abnormal Urinalysis Findings | 0 | 0 |
Urine samples were collected at indicated time points for the analysis of urine parameters including specific gravity and Potential of hydrogen (pH) of urine, presence of glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, and leukocyte esterase in urine.
| Participants | Part 2: Mild Hepatic Impairment Participants | Part 2: Healthy Participants |
|---|---|---|
| Part 2: Number of Participants With Abnormal Urinalysis Findings | 0 | 0 |
Collected over Serious adverse events (SAEs) and non-serious adverse events (Non-SAEs) were collected from the start of the study treatment up to 16 days in each part of the study.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Moderate Hepatic Impairment Participants | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| Part 1: Healthy Participants | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| Part 2: Mild Hepatic Impairment Participants | 0/12 (0%) | 0/12 (0%) | 0/12 (0%) |
| Part 2: Healthy Participants | 0/9 (0%) | 0/9 (0%) | 0/9 (0%) |
| Event | Part 1: Moderate Hepatic Impairment Participants | Part 1: Healthy Participants | Part 2: Mild Hepatic Impairment Participants | Part 2: Healthy Participants |
|---|---|---|---|---|
| ToothacheGastrointestinal disorders | 0/8 | 1/8 | 0/12 | 0/9 |
| Upper respiratory tract infectionInfections and infestations | 0/8 | 1/8 | 0/12 | 0/9 |
| Skin abrasionInjury, poisoning and procedural complications | 1/8 | 0/8 | 0/12 | 0/9 |
| Age, Continuous(Years) | Part 1: Moderate Hepatic Impairment Participants | Part 1: Healthy Participants | Part 2: Mild Hepatic Impairment Participants | Part 2: Healthy Participants | Total |
|---|---|---|---|---|---|
| Mean | 59.5 ± 6.00 | 57.6 ± 7.15 | 61.9 ± 7.55 | 58.7 ± 8.03 | 59.7 ± 7.18 |
| Sex: Female, Male(Participants) | Part 1: Moderate Hepatic Impairment Participants | Part 1: Healthy Participants | Part 2: Mild Hepatic Impairment Participants | Part 2: Healthy Participants | Total |
|---|---|---|---|---|---|
| Female | 1 | 1 | 2 | 2 | 6 |
| Male | 7 | 7 | 10 | 7 | 31 |
| Race/Ethnicity, Customized(Participants) | Part 1: Moderate Hepatic Impairment Participants | Part 1: Healthy Participants | Part 2: Mild Hepatic Impairment Participants | Part 2: Healthy Participants | Total |
|---|---|---|---|---|---|
| BLACK OR AFRICAN AMERICAN | 0 | 2 | 1 | 2 | 5 |
| WHITE - WHITE/CAUCASIAN/EUROPEAN HERITAGE | 8 | 6 | 6 | 6 | 26 |
| ASIAN - EAST ASIAN HERITAGE | 0 | 0 | 1 | 0 | 1 |
| WHITE - ARABIC/NORTH AFRICAN HERITAGE | 0 | 0 | 4 | 1 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2017 to primary completion in Aug 2018, 12 months.
Results were first posted in Sep 2019, 1 year after primary completion.
Of 34 industry-sponsored phase 1 interventional studies under Anemia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 30. This study's 12 months is above that.
Counting every sponsor, half of 48 studies reached it within 12 months; a quarter within 3 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GSK1278863